vs

Side-by-side financial comparison of agilon health, inc. (AGL) and Astrana Health, Inc. (ASTH). Click either name above to swap in a different company.

agilon health, inc. is the larger business by last-quarter revenue ($1.6B vs $950.5M, roughly 1.7× Astrana Health, Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -12.0%, a 12.7% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 3.1%). Astrana Health, Inc. produced more free cash flow last quarter ($-6.0M vs $-23.5M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -1.1%).

agilon health, inc. is a U.S.-based healthcare company partnering with primary care providers to deliver value-based care solutions mainly for senior Medicare beneficiaries. It offers administrative support, clinical tools and risk management frameworks to help physicians improve patient outcomes and cut care costs, operating across over 20 U.S. states.

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

AGL vs ASTH — Head-to-Head

Bigger by revenue
AGL
AGL
1.7× larger
AGL
$1.6B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+39.8% gap
ASTH
42.9%
3.1%
AGL
Higher net margin
ASTH
ASTH
12.7% more per $
ASTH
0.7%
-12.0%
AGL
More free cash flow
ASTH
ASTH
$17.6M more FCF
ASTH
$-6.0M
$-23.5M
AGL
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
-1.1%
AGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AGL
AGL
ASTH
ASTH
Revenue
$1.6B
$950.5M
Net Profit
$-188.9M
$6.6M
Gross Margin
Operating Margin
-12.3%
1.9%
Net Margin
-12.0%
0.7%
Revenue YoY
3.1%
42.9%
Net Profit YoY
-78.5%
184.4%
EPS (diluted)
$0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGL
AGL
ASTH
ASTH
Q4 25
$1.6B
$950.5M
Q3 25
$1.4B
$956.0M
Q2 25
$1.4B
$654.8M
Q1 25
$1.5B
$620.4M
Q4 24
$1.5B
$665.2M
Q3 24
$1.5B
$478.7M
Q2 24
$1.5B
$486.3M
Q1 24
$1.6B
$404.4M
Net Profit
AGL
AGL
ASTH
ASTH
Q4 25
$-188.9M
$6.6M
Q3 25
$-110.2M
$373.0K
Q2 25
$-104.4M
$9.4M
Q1 25
$12.1M
$6.7M
Q4 24
$-105.8M
$-7.8M
Q3 24
$-117.6M
$16.1M
Q2 24
$-30.7M
$19.2M
Q1 24
$-6.1M
$14.8M
Operating Margin
AGL
AGL
ASTH
ASTH
Q4 25
-12.3%
1.9%
Q3 25
-9.1%
2.0%
Q2 25
-8.3%
3.1%
Q1 25
-1.4%
3.3%
Q4 24
-7.1%
0.1%
Q3 24
-9.2%
5.9%
Q2 24
-2.9%
6.2%
Q1 24
-0.4%
7.5%
Net Margin
AGL
AGL
ASTH
ASTH
Q4 25
-12.0%
0.7%
Q3 25
-7.7%
0.0%
Q2 25
-7.5%
1.4%
Q1 25
0.8%
1.1%
Q4 24
-6.9%
-1.2%
Q3 24
-8.1%
3.4%
Q2 24
-2.1%
3.9%
Q1 24
-0.4%
3.7%
EPS (diluted)
AGL
AGL
ASTH
ASTH
Q4 25
$0.12
Q3 25
$0.01
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGL
AGL
ASTH
ASTH
Cash + ST InvestmentsLiquidity on hand
$173.7M
$429.5M
Total DebtLower is stronger
$35.0M
Stockholders' EquityBook value
$126.7M
$779.3M
Total Assets
$1.3B
$2.2B
Debt / EquityLower = less leverage
0.28×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGL
AGL
ASTH
ASTH
Q4 25
$173.7M
$429.5M
Q3 25
$171.7M
$463.4M
Q2 25
$171.4M
$342.1M
Q1 25
$136.9M
$260.9M
Q4 24
$188.2M
$290.8M
Q3 24
$148.2M
$350.3M
Q2 24
$109.5M
$327.7M
Q1 24
$111.7M
$337.3M
Total Debt
AGL
AGL
ASTH
ASTH
Q4 25
$35.0M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AGL
AGL
ASTH
ASTH
Q4 25
$126.7M
$779.3M
Q3 25
$306.1M
$775.5M
Q2 25
$408.9M
$765.5M
Q1 25
$500.3M
$745.4M
Q4 24
$471.0M
$712.7M
Q3 24
$574.9M
$704.6M
Q2 24
$676.6M
$678.9M
Q1 24
$689.3M
$653.5M
Total Assets
AGL
AGL
ASTH
ASTH
Q4 25
$1.3B
$2.2B
Q3 25
$1.6B
$2.2B
Q2 25
$1.7B
$1.4B
Q1 25
$1.9B
$1.3B
Q4 24
$1.7B
$1.4B
Q3 24
$2.1B
$1.3B
Q2 24
$2.2B
$1.3B
Q1 24
$2.3B
$1.2B
Debt / Equity
AGL
AGL
ASTH
ASTH
Q4 25
0.28×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGL
AGL
ASTH
ASTH
Operating Cash FlowLast quarter
$-20.5M
$-2.9M
Free Cash FlowOCF − Capex
$-23.5M
$-6.0M
FCF MarginFCF / Revenue
-1.5%
-0.6%
Capex IntensityCapex / Revenue
0.2%
0.3%
Cash ConversionOCF / Net Profit
-0.44×
TTM Free Cash FlowTrailing 4 quarters
$-119.0M
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGL
AGL
ASTH
ASTH
Q4 25
$-20.5M
$-2.9M
Q3 25
$-18.2M
$10.0M
Q2 25
$-35.1M
$90.9M
Q1 25
$-32.0M
$16.6M
Q4 24
$16.4M
$-10.9M
Q3 24
$-7.7M
$34.0M
Q2 24
$-18.7M
$23.2M
Q1 24
$-47.8M
$6.0M
Free Cash Flow
AGL
AGL
ASTH
ASTH
Q4 25
$-23.5M
$-6.0M
Q3 25
$-21.3M
$7.4M
Q2 25
$-38.3M
$89.5M
Q1 25
$-35.8M
$13.6M
Q4 24
$13.2M
$-13.5M
Q3 24
$-11.2M
$31.7M
Q2 24
$-22.0M
$20.4M
Q1 24
$-50.9M
$5.6M
FCF Margin
AGL
AGL
ASTH
ASTH
Q4 25
-1.5%
-0.6%
Q3 25
-1.5%
0.8%
Q2 25
-2.7%
13.7%
Q1 25
-2.3%
2.2%
Q4 24
0.9%
-2.0%
Q3 24
-0.8%
6.6%
Q2 24
-1.5%
4.2%
Q1 24
-3.2%
1.4%
Capex Intensity
AGL
AGL
ASTH
ASTH
Q4 25
0.2%
0.3%
Q3 25
0.2%
0.3%
Q2 25
0.2%
0.2%
Q1 25
0.3%
0.5%
Q4 24
0.2%
0.4%
Q3 24
0.2%
0.5%
Q2 24
0.2%
0.6%
Q1 24
0.2%
0.1%
Cash Conversion
AGL
AGL
ASTH
ASTH
Q4 25
-0.44×
Q3 25
26.69×
Q2 25
9.65×
Q1 25
-2.64×
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AGL
AGL

Medical Services$1.6B100%
Other Operating$2.5M0%

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

Related Comparisons